WO1999038972A8 - Human genes and gene expression products ii - Google Patents

Human genes and gene expression products ii

Info

Publication number
WO1999038972A8
WO1999038972A8 PCT/US1999/001619 US9901619W WO9938972A8 WO 1999038972 A8 WO1999038972 A8 WO 1999038972A8 US 9901619 W US9901619 W US 9901619W WO 9938972 A8 WO9938972 A8 WO 9938972A8
Authority
WO
WIPO (PCT)
Prior art keywords
genes
gene expression
expression products
human genes
polynucleotides
Prior art date
Application number
PCT/US1999/001619
Other languages
French (fr)
Other versions
WO1999038972A3 (en
WO1999038972A2 (en
WO1999038972A9 (en
Inventor
Lewis T Williams
Jaime Escobedo
Michael A Innis
Pablo Dominguez Garcia
Julie Sudduth-Klinger
Christoph Reinhard
Klaus Giese
Filippo Randazzo
Giulia C Kennedy
David Pot
Altaf Kassam
George Lamson
Radoje Drmanac
Radomir Crkvenjakov
Mark Dickson
Snezana Drmanac
Ivan Labat
Dena Leshkowitz
David Kita
Veronica Garcia
Lee William Jones
Birgit Stache-Crain
Original Assignee
Chiron Corp
Hyseq Inc
Lewis T Williams
Jaime Escobedo
Michael A Innis
Pablo Dominguez Garcia
Sudduth Klinger Julie
Christoph Reinhard
Klaus Giese
Filippo Randazzo
Giulia C Kennedy
David Pot
Altaf Kassam
George Lamson
Radoje Drmanac
Radomir Crkvenjakov
Mark Dickson
Snezana Drmanac
Ivan Labat
Dena Leshkowitz
David Kita
Veronica Garcia
Lee William Jones
Stache Crain Birgit
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp, Hyseq Inc, Lewis T Williams, Jaime Escobedo, Michael A Innis, Pablo Dominguez Garcia, Sudduth Klinger Julie, Christoph Reinhard, Klaus Giese, Filippo Randazzo, Giulia C Kennedy, David Pot, Altaf Kassam, George Lamson, Radoje Drmanac, Radomir Crkvenjakov, Mark Dickson, Snezana Drmanac, Ivan Labat, Dena Leshkowitz, David Kita, Veronica Garcia, Lee William Jones, Stache Crain Birgit filed Critical Chiron Corp
Priority to EP99904288A priority Critical patent/EP1053319A2/en
Priority to AU24716/99A priority patent/AU2471699A/en
Priority to JP2000556580A priority patent/JP2002519000A/en
Priority to US09/297,648 priority patent/US6964868B1/en
Publication of WO1999038972A2 publication Critical patent/WO1999038972A2/en
Publication of WO1999038972A3 publication Critical patent/WO1999038972A3/en
Publication of WO1999038972A8 publication Critical patent/WO1999038972A8/en
Publication of WO1999038972A9 publication Critical patent/WO1999038972A9/en
Priority to US10/779,543 priority patent/US8101349B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

This invention relates to novel human polynucleotides and variants thereof, their encoded polypeptides and variants thereof, to genes corresponding to these polynucleotides and to proteins expressed by the genes. The invention also relates to diagnostic and therapeutic agents employing such novel human polynucleotides, their corresponding genes or gene products, e.g., these genes and proteins, including probes, antisense constructs, and antibodies.
PCT/US1999/001619 1997-12-23 1999-01-28 Human genes and gene expression products ii WO1999038972A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP99904288A EP1053319A2 (en) 1998-01-28 1999-01-28 Human genes and gene expression products ii
AU24716/99A AU2471699A (en) 1998-01-28 1999-01-28 Human genes and gene expression products ii
JP2000556580A JP2002519000A (en) 1998-01-28 1999-01-28 Human genes and gene expression products II
US09/297,648 US6964868B1 (en) 1998-01-28 1999-01-28 Human genes and gene expression products II
US10/779,543 US8101349B2 (en) 1997-12-23 2004-02-12 Gene products differentially expressed in cancerous cells and their methods of use II

Applications Claiming Priority (14)

Application Number Priority Date Filing Date Title
US7291098P 1998-01-28 1998-01-28
US7595498P 1998-02-24 1998-02-24
US8011498P 1998-03-31 1998-03-31
US8066698P 1998-04-03 1998-04-03
US8051598P 1998-04-03 1998-04-03
US10523498P 1998-10-21 1998-10-21
US10587798P 1998-10-27 1998-10-27
US60/080,114 1998-10-28
US60/072,910 1998-10-28
US60/080,515 1998-10-28
US60/075,954 1998-10-28
US60/080,666 1998-10-28
US60/105,877 1998-12-21
US60/105,234 1998-12-21

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/779,543 Continuation-In-Part US8101349B2 (en) 1997-12-23 2004-02-12 Gene products differentially expressed in cancerous cells and their methods of use II

Publications (4)

Publication Number Publication Date
WO1999038972A2 WO1999038972A2 (en) 1999-08-05
WO1999038972A3 WO1999038972A3 (en) 1999-12-23
WO1999038972A8 true WO1999038972A8 (en) 2000-04-06
WO1999038972A9 WO1999038972A9 (en) 2001-05-17

Family

ID=27568324

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/001619 WO1999038972A2 (en) 1997-12-23 1999-01-28 Human genes and gene expression products ii

Country Status (3)

Country Link
EP (1) EP1053319A2 (en)
JP (1) JP2002519000A (en)
WO (1) WO1999038972A2 (en)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001066740A2 (en) * 2000-03-03 2001-09-13 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
AU4362199A (en) * 1998-05-18 1999-12-06 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Proteins and genes useful as tumor markers
US6395877B1 (en) 1998-06-30 2002-05-28 Millennium Pharmaceuticals, Inc. 14273 receptor, a novel G-protein coupled receptor
US6448005B1 (en) * 1998-06-30 2002-09-10 Millennium Pharmaceuticals, Inc. 14723 Receptor, a novel G-protein coupled receptor
US7534579B2 (en) 1998-06-30 2009-05-19 Millennium Pharmaceuticals, Inc. 14273 receptor, a novel G-protein coupled receptor
WO2000000611A2 (en) * 1998-06-30 2000-01-06 Millennium Pharmaceuticals, Inc. 14273 receptor, a g-protein coupled receptor
WO2000008156A2 (en) * 1998-08-07 2000-02-17 Incyte Pharmaceuticals, Inc. Dna replication- and repair-associated proteins
AU2854600A (en) * 1999-01-25 2000-08-07 Zymogenetics Inc. Human polypeptide having multiple epidermal growth factor (egf) -like domains, zntr2
US6759508B2 (en) 2000-09-01 2004-07-06 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
AU5134600A (en) * 1999-05-14 2000-12-05 Incyte Genomics, Inc. Full-length molecules expressed in human tissues
CA2373616A1 (en) * 1999-05-19 2000-11-23 Human Genome Sciences, Inc. Tm4sf receptors
AU5048200A (en) * 1999-05-27 2000-12-18 Incyte Genomics, Inc. Sorting nexins
FR2795414B1 (en) * 1999-06-22 2002-07-05 Ass Pour Le Dev De La Rech En POLYPEPTIDE ICBP90 AND ITS FRAGMENTS AND POLYNUCLEOTIDES ENCODING SAID POLYPEPTIDES AND APPLICATIONS TO THE DIAGNOSIS AND TREATMENT OF CANCER
DE19935303A1 (en) * 1999-07-28 2001-02-08 Aventis Pharma Gmbh Oligonucleotides to inhibit the expression of human eg5
ES2272309T3 (en) 1999-08-03 2007-05-01 Millennium Pharmaceuticals, Inc. 15571, A NEW GPCR TYPE MOLECULA OF THE SECRETINE TYPE FAMILY AND ITS USES.
JP2003531572A (en) * 1999-09-24 2003-10-28 レキシコン・ジェネティクス・インコーポレーテッド Novel human protein such as endothelin converting enzyme and polynucleotide encoding the same
ES2189560B1 (en) 1999-10-01 2005-01-01 Consejo Superior De Investigaciones Cientificas DNA POLYMERASE K, NEW TUMOR MARKER.
US6518052B1 (en) 1999-10-22 2003-02-11 Bristol-Myers Squibb Company Human homologue of yeast helicase and uses thereof
US6893818B1 (en) 1999-10-28 2005-05-17 Agensys, Inc. Gene upregulated in cancers of the prostate
US6428980B1 (en) 1999-11-16 2002-08-06 Rigel Pharmaceuticals, Inc. Nucleic acids encoding RIP3 associated cell cycle proteins
AUPQ421699A0 (en) 1999-11-24 1999-12-16 University Of Western Australia, The Tumour suppressor factor
US20030109428A1 (en) 1999-12-01 2003-06-12 John Bertin Novel molecules of the card-related protein family and uses thereof
EP1967586B1 (en) 2000-01-26 2011-03-09 Agensys, Inc. 84P2A9: A prostate and testis specific protein highly expressed in prostate cancer
US6566502B1 (en) * 2000-01-28 2003-05-20 Eos Biotechnology, Inc. Methods of diagnosing cancer, compositions, and methods of screening for cancer modulators
US20020137675A1 (en) * 2000-02-08 2002-09-26 Taupier Raymond J. Polynucleotides and polypeptides encoded thereby
CA2401670A1 (en) * 2000-03-01 2001-09-07 Incyte Genomics, Inc. Human enzyme molecules
US6511834B1 (en) 2000-03-24 2003-01-28 Millennium Pharmaceuticals, Inc. 32142,21481,25964,21686, novel human dehydrogenase molecules and uses therefor
US6627423B2 (en) 2000-03-24 2003-09-30 Millennium Pharmaceuticals, Inc. 21481, a novel dehydrogenase molecule and uses therefor
WO2001092491A2 (en) * 2000-05-30 2001-12-06 Sugen, Inc. Mammalian protein phosphatases identified by in-silico analysis
EP1659177A3 (en) * 2000-06-02 2006-05-31 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids ancoding the same
ES2398391T3 (en) * 2000-06-15 2013-03-15 Novartis Vaccines And Diagnostics, Inc. Polynucleotides related to colon cancer
AU2001273148A1 (en) * 2000-06-30 2002-01-14 Millennium Pharmaceuticals, Inc. 57658, a human uridine kinase and uses thereof
FR2812305B1 (en) * 2000-07-28 2005-01-07 Commissariat Energie Atomique DNA MEMBER PROMOTING TRANSCRIPTION ACTIVITY, ACTIVE IN HUMAN CELLS AND GENERAL METHOD FOR ADJUSTING ACTIVITY
US7060456B2 (en) 2000-08-30 2006-06-13 Bayer Healthcare Ag Regulation of human protein phosphatase IIc-like enzyme
AU2002213084A1 (en) * 2000-10-11 2002-04-22 Avalon Pharmaceuticals Cancer-linked genes as targets for chemotherapy
JP2004535785A (en) * 2000-11-22 2004-12-02 ディアデクサス インコーポレーテッド Compositions and methods for breast-specific genes and proteins
WO2002046383A2 (en) * 2000-12-08 2002-06-13 Incyte Genomics, Inc. Protein modification and maintenance molecules
EP1239051A3 (en) * 2001-01-30 2004-03-17 Aeomica, Inc. Human posh-like protein 1
US7601825B2 (en) 2001-03-05 2009-10-13 Agensys, Inc. Nucleic acid and corresponding protein entitled 121P1F1 useful in treatment and detection of cancer
US6924358B2 (en) 2001-03-05 2005-08-02 Agensys, Inc. 121P1F1: a tissue specific protein highly expressed in various cancers
CA2443123A1 (en) 2001-04-10 2002-10-24 Agensys, Inc. Nuleic acids and corresponding proteins useful in the detection and treatment of various cancers
US7927597B2 (en) 2001-04-10 2011-04-19 Agensys, Inc. Methods to inhibit cell growth
JPWO2002088349A1 (en) * 2001-04-27 2004-08-19 株式会社ジェノックス創薬研究所 Method for testing allergic disease using alternative splicing form of cathepsin C as index
US7157558B2 (en) 2001-06-01 2007-01-02 Genentech, Inc. Polypeptide encoded by a polynucleotide overexpresses in tumors
AU2002327176A1 (en) * 2001-06-06 2002-12-16 Human Genome Sciences, Inc. 20 human secreted proteins
AT410945B (en) * 2001-06-27 2003-08-25 Burkhard Dr Jansen Diagnosis of multiple sclerosis or tumors, by detecting absence of wild-type stem cell factor-apoptosis response gene, or the derived protein, also new nucleic acids
EP1438427B1 (en) * 2001-09-14 2016-04-20 Clinical Genomics Pty. Ltd Nucleic acid markers for use in determining predisposition to neoplasm and/or adenoma
WO2003043565A2 (en) * 2001-09-24 2003-05-30 University Of Aarhus Methods for diagnosis and treatment of diseases associated with altered expression of nrf2
EP1430128B1 (en) * 2001-09-28 2018-04-25 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Micro-rna molecules
US7449548B2 (en) 2001-12-07 2008-11-11 Agensys, Inc. Nucleic acid and corresponding protein entitled 193P1E1B useful in treatment and detection of cancer
CA2432937A1 (en) * 2002-03-07 2003-09-07 Bf Research Institute, Inc. P18abrp gene and p18abrp protein, and novel gene/protein (p60trp) suppressing cell death and substances promoting cell death by interaction with the same
JP2005527614A (en) 2002-05-29 2005-09-15 デヴェロゲン アクチエンゲゼルシャフト フュア エントヴィックルングスビオローギッシェ フォルシュング Pancreas-specific protein
US20040081653A1 (en) 2002-08-16 2004-04-29 Raitano Arthur B. Nucleic acids and corresponding proteins entitled 251P5G2 useful in treatment and detection of cancer
CA2496236A1 (en) * 2002-08-21 2004-03-04 Takeda Pharmaceutical Company Limited Preventives/remedies for cancer
TW200413725A (en) * 2002-09-30 2004-08-01 Oncotherapy Science Inc Method for diagnosing non-small cell lung cancers
EP1608684A2 (en) 2003-02-07 2005-12-28 Protein Design Labs, Inc. Amphiregulin antibodies and their use to treat cancer and psoriasis
US20050186577A1 (en) 2004-02-20 2005-08-25 Yixin Wang Breast cancer prognostics
EP2007364A4 (en) 2006-04-07 2009-11-11 Biopharmica Ltd Transcription factor modulator
CN103757028B (en) * 2014-01-23 2015-09-09 南京医科大学 OSBPL2 mutated genes, its authentication method and detection kit

Also Published As

Publication number Publication date
WO1999038972A3 (en) 1999-12-23
EP1053319A2 (en) 2000-11-22
WO1999038972A2 (en) 1999-08-05
WO1999038972A9 (en) 2001-05-17
JP2002519000A (en) 2002-07-02

Similar Documents

Publication Publication Date Title
WO1999038972A3 (en) Human genes and gene expression products ii
WO1999058675A3 (en) Human genes and gene expression products v
WO1999033982A3 (en) Human genes and gene expression products i
WO2002014500A3 (en) Human genes and gene expression products
WO2001066753A3 (en) Human genes and gene expression products
WO2000040614A3 (en) Characterization of the soc/crac calcium channel protein family
MXPA02011656A (en) Nrg 2 nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods.
EP1005540A4 (en) Ikk-beta proteins, nucleic acids and methods
WO2002029086A3 (en) Nucleic acid sequences differentially expressed in cancer tissue
WO2001005825A3 (en) Nucleic acid sequences encoding putative angiopoietin proteins
WO1999064594A3 (en) Genes and gene expression products that are differentially regulated in prostate cancer
WO1999053040A3 (en) Human nucleic acid sequences from ovarian tumour tissue
WO2002044320A3 (en) Human elongase genes and uses thereof
WO2000012702A3 (en) Human genes differentially expressed in colorectal cancer
WO2001064877A3 (en) Human schizophrenia gene
WO2000077239A3 (en) Novel genes encoding proteins having diagnostic, preventive, therapeutic, and other uses
WO2003050236A3 (en) Human genes and gene expression products isolated from human prostate
WO2000018916A3 (en) Human genes and gene expression products
WO2001072781A3 (en) Human genes and expression products
WO2001064876A3 (en) Human schizophrenia gene
WO1999046375A3 (en) Human nucleic acid sequences from prostate tissue
WO2001014415A3 (en) Egfh2 genes and gene products
WO2001000638A3 (en) Novel genes encoding proteins having diagnostic, preventive, therapeutic, and other uses
WO2002055700A8 (en) Human genes and gene expression products isolated from human prostate
WO1999046381A3 (en) Human fgf gene and gene expression products

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 09297648

Country of ref document: US

AK Designated states

Kind code of ref document: C1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: PAT. BUL. 31/99 UNDER (30) ADD "60/105234 21.10.98 US 60/105877 20.10.98 US"

ENP Entry into the national phase in:

Ref country code: JP

Ref document number: 2000 556580

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1999904288

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1999904288

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

AK Designated states

Kind code of ref document: C2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 131, 132, 591-594 AND 638-652, DESCRIPTION, REPLACED BY NEW PAGES 131, 132, 591-594 AND 638-652; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

WWW Wipo information: withdrawn in national office

Ref document number: 1999904288

Country of ref document: EP